Analysts’ Top Healthcare Picks: Agios Pharma (AGIO), Intra-Cellular Therapies (ITCI)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agios Pharma (NASDAQ:AGIO), Intra-Cellular Therapies (NASDAQ:ITCI) and Adaptimmune Therapeutics (NASDAQ:ADAP) with bullish sentiments.

Agios Pharma (AGIO)

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Agios Pharma, with a price target of $90. The company’s shares opened today at $88.79.

According to TipRanks.com, Newman is a 5-star analyst with an average return of 17.7% and a 45.0% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Atara Biotherapeutics.

Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $104.14, a 17.3% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $125 price target.

.

See today’s analyst top recommended stocks >>

Intra-Cellular Therapies (ITCI)

In a report released today, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Intra-Cellular Therapies, with a price target of $31. The company’s shares opened today at $20.62.

Kulkarni observed:

“We eagerly await the FDA’s potential acceptance of this NDA. Ahead of a potentially important period for the company, our thesis on the stock is unchanged. Specifically, in our view: 1) lumateperone, if approved, could become a meaningful competitor in the schizophrenia space given its benign safety/tolerability profile vs. the current standard of care; 2) ITCI presents scarcity value in that it is one of the few companies with promising late-stage assets in the neuropsychiatry space, where pipeline success remains somewhat elusive.”

According to TipRanks.com, Kulkarni is a 3-star analyst with an average return of 3.1% and a 45.2% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Alder Biopharmaceuticals, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Intra-Cellular Therapies is a Moderate Buy with an average price target of $29.50, a 43.1% upside from current levels. In a report issued on July 23, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $28 price target.

.

Adaptimmune Therapeutics (ADAP)

Cowen & Co. analyst Marc Frahm maintained a Buy rating on Adaptimmune Therapeutics today. The company’s shares opened today at $9.67.

According to TipRanks.com, Frahm is a 1-star analyst with an average return of -1.1% and a 42.9% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Blueprint Medicines, and Incyte Corp.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adaptimmune Therapeutics with a $19 average price target, representing a 96.5% upside. In a report issued on July 18, Raymond James also maintained a Buy rating on the stock.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts